AZN Stock Gains as COPD Drug Clears Two Late-Stage Studies

The two studies — OBERON and TITANIA — evaluated the drug against placebo in adults with symptomatic COPD who had a history of at least two moderate or at least one severe COPD exacerbations (or ...
Morningstar

AstraZeneca Shares Rise After Lung Drug Hits Goals in Late-Stage Trials — Update

AstraZeneca shares rose after the company said a drug candidate met the primary goal in two late-stage trials for a deadly lung disease, clearing the path to seek approval from regulators. The U.K.

AstraZeneca Shares Surge on COPD Trial Success

AstraZeneca shares were up about 3.5% Friday after the company said its drug for COPD, a deadly lung disease often caused by smoking, slowed patients' symptoms in two large trials. The drug, ...